BioSpace News Archive

Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the second quarter of 2020. The dividend will be paid on the closing date of AbbVie’s pending acquisition of Allergan, which remains subject to regulatory approval and customary closing conditions, or on June

Onconova Therapeutics, Inc. today announced that the Company will release its year-end 2019 financial results on Tuesday, March 24, 2020, after the market closes. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these resu

- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash on March 31, 2020 in excess of $80 million expected to be sufficient to fund company through Phase 2b trial in PGHD data read-out

Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-Beta antisense drug candidate, today provided an update on its rapid antiviral response program against coronaviruses, with a target of the coronavirus, initially the COVID-19 virus.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that it has entered into definitive agreements with healthcare focused institutional investors that provide for the purchase and sale of an aggregate of 6,257,144 shares of its Class A Common Stock, or common stock, at a purchase price of $0.35 per share in a registered direct offering, resu

Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for the year ended December 31, 2019. Key Developments Entered into an exclusive worldwide collaboration and option to license agreement on September 20, 2019 with ADT Pharmaceuticals, LLC (“ADT”) to develop novel small-molecule pan-RAS inhibitors a

Award to help fund a Phase 1/2 clinical trial of the company’s Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for drug-resistant respiratory infections in cystic fibrosis patients Armata to collaborate with the Cystic Fibrosis Therapeutics Development Network [18-March-2020] MARINA DEL REY, Calif. , March 18, 2020 /PRNewswire/ -- Armata Phar

FUJIFILM Corporation announced today that it will invest approximately 9 billion yen ($83M USD) to expand the microbial production capacity of FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development & Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies

IVERIC bio today announced that due to the threat of the coronavirus (COVID-19) global pandemic, the Company has decided to delay the initiation of enrollment of patients in the second pivotal clinical trial for Zim

Nebraska HIE participants will now have a single, holistic view of over 4 million patients